Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis
Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplan...
Gespeichert in:
Veröffentlicht in: | Pediatric blood & cancer 2021-03, Vol.68 (3), p.e28852-n/a |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR |
---|---|
ISSN: | 1545-5009 1545-5017 |
DOI: | 10.1002/pbc.28852 |